306 top medical experts on Pseudomyxoma Peritonei across 34 countries and 22 U.S. states, including 192 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Pseudomyxoma Peritonei: A peritoneal adenocarcinoma characterized by build-up of mucus in the peritoneal cavity. Mucus secreting cells may attach to the peritoneal lining and continue to secrete mucus. The majority of cases represent tumor spread from a primary low-grade mucinous neoplasm of the appendix (NCI Thesaurus).
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Mucinous Adenocarcinoma (3,233).
  4. Clinical Trials ClinicalTrials.gov : at least 24 including 2 Active, 8 Completed, 8 Recruiting
  5. Synonyms: Gelatinous Ascites


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Sugarbaker, Paul Hendrick   Surgical Oncology   Google Publications
    Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center, Washington, District Columbia, USA.
    Physician  Highly Cited  Highly Published  Case Reports 
    Subjects: Peritoneal Neoplasms; Appendiceal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Adenocarcinoma, Mucinous; Cytoreduction Surgical Procedures
    Categories: Therapy; Pathology; Surgery; Drug Therapy; Administration & Dosage; Methods
    Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. (2012)
    A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. (2016)

  2. Sardi, Armando   Surgical Oncology   ClinicalTrials.gov Google Publications
    Division of Surgery, Department of Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, Maryland.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: Other (MD, 1980)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 65/100
    Disclosed payments in 2021 from 10 biomedical companies, totalling $247.49, including $112.01 from  Ethicon US, LLC
    Subjects: Peritoneal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Procedures; Anti-Bacterial Agents; Appendiceal Neoplasms
    Categories: Microbiology; Therapy; Surgery; Therapeutic Use; Administration & Dosage; Drug Therapy
    Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. (2012)
    The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. (2021)

  3. Levine, Edward A   Surgery  Google Publications
    Surgical Oncology Service, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina.
    Physician  Highly Cited  Highly Published 
    Subjects: Peritoneal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Cytoreduction Surgical Procedures; Hyperthermia, Induced
    Categories: Therapy; Administration & Dosage; Diagnostic Imaging; Surgery; Pathology; Standards
    Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. (2012)
    The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. (2021)

  4. Bowne, Wilbur B   Surgery   Google Publications
    Department of Surgery, Drexel University College of Medicine, Philadelphia, PA, 19102, USA. .
    Physician 
    Medical school: State University of Ny Upstate Medical University (MD, 1994)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 100/100
    Disclosed payments from biomedical company (AngioDynamics, Inc.) in 2021 for $207.75
    Subjects: Biomarkers, Tumor; Peritoneal Neoplasms; Appendix; Chromogranins; Drug Delivery Systems
    Categories: Genetics; Metabolism; Chemistry; Administration & Dosage; Methods; Pathology
    Toward the molecular dissection of peritoneal pseudomyxoma. (2016)
    Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy. (2018)

  5. Moran, Brendan John     Google Publications
    Basingstoke and North Hampshire National Health Service Foundation Trust, Basingstoke, United Kingdom.
    Physician  Highly Cited  Highly Published  Guideline  Case Reports 
    Subjects: Peritoneal Neoplasms; Appendiceal Neoplasms; Cytoreduction Surgical Procedures; Hyperthermia, Induced; Antineoplastic Combined Chemotherapy Protocols
    Categories: Surgery; Therapy; Pathology; Metabolism; Methods; Diagnosis
    Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. (2012)
    A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. (2016)

  6. Overman, Michael J   Medical Oncology  Google Publications
    Department of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
    Physician  Highly Published 
    Medical school: Johns Hopkins University School of Medicine (MD, 2000)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments in 2021 from 9 biomedical companies, totalling $28,060.53, including $6,000 from  Merck Sharp & Dohme Corporation
    Subjects: Peritoneal Neoplasms; Appendiceal Neoplasms; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell
    Categories: Drug Therapy; Pathology; Diagnostic Imaging; Administration & Dosage; Surgery
    Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. (2015)
    A Simplified Preoperative Assessment Predicts Complete Cytoreduction and Outcomes in Patients with Low-Grade Mucinous Adenocarcinoma of the Appendix. (2015)

  7. Fournier, Keith F   Surgical Oncology  ClinicalTrials.gov Google Publications
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
    Physician  Highly Published 
    Medical school: Geisel School of Medicine at Dartmouth (MD, 2000)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Subjects: Peritoneal Neoplasms; Appendiceal Neoplasms; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell
    Categories: Drug Therapy; Pathology; Diagnostic Imaging; Administration & Dosage; Surgery
    Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. (2015)
    A Simplified Preoperative Assessment Predicts Complete Cytoreduction and Outcomes in Patients with Low-Grade Mucinous Adenocarcinoma of the Appendix. (2015)

  8. Bartlett, David L   Surgical Oncology  Google Publications
    Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, PA, USA.
    Physician  Highly Published  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 79.1/100
    Subjects: Peritoneal Neoplasms; Appendiceal Neoplasms; Hyperthermia, Induced; Cytoreduction Surgical Procedures; Mucin-2
    Categories: Therapy; Administration & Dosage; Pathology; Mortality; Adverse Effects; Biosynthesis
    Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei. (2018)
    Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei. (2019)

  9. Loggie, Brian W   Surgical Oncology  Google Publications
    Department of Surgery, Creighton University, Omaha, Nebraska, United States of America.
    Physician  Highly Published 
    Subjects: Peritoneal Neoplasms; Inflammation; Mutation; Tumor Microenvironment; Appendectomy
    Categories: Metabolism; Genetics; Pathology; Classification; Drug Therapy; Methods
    Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. (2013)
    Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. (2013)

  10. Baumgartner, Joel M   Surgical Oncology   Google Publications
    Division of Surgical Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA, USA. . Top Hospital
    Physician  Clinical Trial 
    Subjects: Appendiceal Neoplasms; Peritoneal Neoplasms; Adenocarcinoma, Mucinous; Ascites; Drainage
    Categories: Diagnosis; Surgery; Methods; Metabolism
    Overinterpretation is common in pathological diagnosis of appendix cancer during patient referral for oncologic care. (2017)
    Laparoscopic evacuation of mucinous ascites for palliation of pseudomyxoma peritonei. (2015)

  11. Glehen, Olivier     Google Publications
    Department of General Surgery and Surgical Oncology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports 
    Subjects: Peritoneal Neoplasms; Hyperthermia, Induced; Cytoreduction Surgical Procedures; Appendiceal Neoplasms; Antineoplastic Combined Chemotherapy Protocols
    Categories: Therapy; Methods; Surgery; Pathology; Metabolism; Diagnosis
    Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. (2012)
    Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. (2021)

  12. Sarpel, Umut   Surgery   Google Publications
    Division of Surgical Oncology, Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA. . Top Hospital
    Physician  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72.4/100
    Subjects: Appendiceal Neoplasms; Peritoneal Neoplasms; Adenocarcinoma, Mucinous; Carcinoma; Colorectal Neoplasms
    Categories: Diagnosis; Pathology; Therapy; Administration & Dosage; Secondary
    Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. (2014)
    A unique presentation of superinfected pseudomyxoma peritonei secondary to a low-grade appendiceal mucinous neoplasm. (2019)

  13. Zeh, Herbert J   Surgical Oncology  Google Publications
    University of Texas Southwestern Medical Center, Dallas, TX, USA. Top Hospital
    Physician  Highly Published 
    Subjects: Peritoneal Neoplasms; Appendiceal Neoplasms; Cytoreduction Surgical Procedures; Hyperthermia, Induced; Mucin-2
    Categories: Therapy; Pathology; Administration & Dosage; Mortality; Adverse Effects; Biosynthesis
    Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei. (2018)
    Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei. (2019)

  14. Menias, Christine O   Diagnostic Radiology  Google Publications
    Department of Radiology Phoenix, Mayo Clinic Arizona, Phoenix, AZ, USA. Top Hospital
    Physician  Highly Published 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 69/100
    Subjects: Peritoneal Neoplasms; Adenocarcinoma, Mucinous; Carcinoma; Appendiceal Neoplasms
    Categories: Diagnostic Imaging; Surgery
    Borderline epithelial ovarian tumors: what the radiologist should know. (2021)
    Mucinous appendiceal neoplasms: classification, imaging, and HIPEC. (2019)

  15. Grotz, Travis E   Surgery  Google Publications
    Department of Hepatobiliary and Pancreatic Surgery, Mayo Clinic, Rochester, MN, USA. Top Hospital
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Subjects: Peritoneal Neoplasms; Adenocarcinoma, Mucinous; Appendectomy; Appendiceal Neoplasms; Colectomy
    Categories: Diagnostic Imaging; Genetics; Methods; Surgery
    Mucinous appendiceal neoplasms: classification, imaging, and HIPEC. (2019)
    Right hemicolectomy is not routinely indicated in pseudomyxoma peritonei. (2012)

  16. Taggart, Melissa W   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Subjects: Peritoneal Neoplasms; Appendiceal Neoplasms; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Mucin-1
    Categories: Pathology; Diagnosis; Drug Therapy; Surgery; Administration & Dosage; Metabolism
    Acellular mucin in pseudomyxoma peritonei of appendiceal origin: what is adequate sampling for histopathology? (2020)
    Is malignant dedifferentiation for mucinous appendiceal neoplasms a valid phenomenon or merely histopathologic ambiguity? (2011)

  17. Gleeson, Elizabeth M   Surgery  Google Publications
    Drexel University College of Medicine, Philadelphia, PA.
    Physician 
    Subjects: Biomarkers, Tumor; Appendix; Chromogranins; GTP-Binding Protein alpha Subunits, Gs; Gene Expression Profiling
    Categories: Genetics; Methods; Pathology
    Toward the molecular dissection of peritoneal pseudomyxoma. (2016)
    Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy. (2018)

  18. Deraco, Marcello   Google Publications
    Peritoneal Surface Malignancies Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico IRCCS, Istituto Nazionale Tumori dei Tumori di Milano, Milano, Italy.
    Scientist  Highly Cited  Highly Published  Guideline  Clinical Trial 
    Subjects: Peritoneal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Cytoreduction Surgical Procedures; Hyperthermia, Induced
    Categories: Therapy; Drug Therapy; Genetics; Administration & Dosage; Pathology; Methods
    Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. (2012)
    Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. (2021)

  19. Valasek, Mark A   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Pathology, University of California, San Diego, CA. Top Hospital
    Physician 
    Disclosed payments in 2021 from 11 biomedical companies, totalling $127,900, including $114,000 from  ABBVIE INC.
    Subjects: Adenocarcinoma, Mucinous; Appendiceal Neoplasms; Ovarian Neoplasms
    Categories: Diagnosis; Pathology
    An Update on the Diagnosis, Grading, and Staging of Appendiceal Mucinous Neoplasms. (2018)
    Overinterpretation is common in pathological diagnosis of appendix cancer during patient referral for oncologic care. (2017)

  20. Ioffe, Olga B   Anatomic Pathology  Google Publications
    1 University of Maryland Medical Center, Baltimore, MD, USA.
    Physician  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 100/100
    Subjects: Appendiceal Neoplasms; Peritoneal Neoplasms; Biomarkers, Tumor; Endometrial Stromal Tumors; Fallopian Tube Neoplasms
    Categories: Pathology; Diagnosis; Metabolism
    Pseudomyxoma Endometrii: Endometrial Deposition of Acellular Mucin from a Low-Grade Appendiceal Mucinous Neoplasm as a Rare Mimic of Myxoid Uterine Tumors. (2015)
    Fallopian Tube Involvement by Disseminated Peritoneal Adenomucinosis, Mimicking Mucinous Tubal Metaplasia. (2017)

Note:
  1. These experts have limited publications on this topic in our database, so expertise assessment may not be accurate.
  2. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);